Last Posted: May 31, 2019
- New Drugs, New Side Effects: Complications of Cancer Immunotherapy
NCI, May 2019 - Assessment of tumor mutation burden calculation from gene panel sequencing data.
Xu Zhenwu et al. OncoTargets and therapy 2019 123401-3409 - Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small-Cell Lung Cancer.
Fang Wenfeng et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 May - Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
Lheureux Stephanie et al. CA: a cancer journal for clinicians 2019 May - [Targeted gene sequencing panels: applicability for neoantigen profiling of colon and rectal adenocarcinoma].
Kanygina A V et al. Biomeditsinskaia khimiia 2018 Nov 64(6) 517-524 - A multigene assay determines risk of recurrence in patients with triple-negative breast cancer.
Stewart Rachel L et al. Cancer research 2019 May - ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C et al. Annals of oncology : official journal of the European Society for Medical Oncology 2019 May - Combination immunotherapy: the emerging treatment that removes cancer's "cloak of invisibility".
Torjesen Ingrid et al. BMJ (Clinical research ed.) 2019 Apr 365l1824 - Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.
Haslam Alyson, et al. JAMA network open 2019 5 0. (5) e192535 - Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology.
Bristow Robert G et al. The Lancet. Oncology 2018 19(5) e240-e251
.png)
No hay comentarios:
Publicar un comentario